Synapse - Howard Scher

Search Within

Howard Scher

Results (1133)

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary results

Meeting Abstract

Slovin, S. F.; Kargman, M.; Durso, R.; Curley, T.; Israel, R. J.; Olson, W. C.; Morris, S.; Murphy, D.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload

Meeting Abstract

Morris, M. J.; Farrelly, J. S.; Fox, J. J.; Dennis, E. R.; Schwartz, L. H.; Schoder, H.; Haupt, E. C.; Borwick, L. S.; Larson, S. M.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study

Meeting Abstract

Higano, C. S.; Beer, T. M.; Taplin, M.; Efstathiou, E.; Anand, A.; Hirmand, M.; Fleisher, M.; Scher, H. I.; for the Prostate Cancer Clinical Trials Consortium
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Genomic analysis of circulating tumor cells to evaluate predictive biomarkers

Meeting Abstract

Danila, D. C.; Anand, A.; Yao, J.; Gierszewska, M.; Kramer, M.; Fleisher, M.; Sawyers, C. L.; McCombie, W. R.; Scher, H. I.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Molecular profiling of circulating tumor cells (CTC) in patients with castrate resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy

Meeting Abstract

Danila, D. C.; Anand, A.; Sung, C. C.; Leversha, M.; Cao, L.; Fleisher, M.; Scher, H. I.
Cancer Research (2011)

Fulltext@MSK | Save

The AR axis as a pathogenetic mechanism and therapeutic target throughout the clinical states of prostate cancer: Opportunities for second-line hormonal manipulations in castration-resistant prostate cancer

Book Section

Mitsiades, N.; Chen, Y.; Scher, H. I.
In Scardino, P. T.; Linehan, W. M.; Zelefsky, M. J.; Vogelzang, N. J.; Sheinfeld, J.; Rini, B. I.; Bochner, B. H. (Eds.) Comprehensive Textbook of Genitourinary Oncology. 4th ed (2011)

Fulltext@MSK | Save

Circulating tumors cells as biomarkers: Progress toward biomarker qualification

Journal Article

Danila, D. C.; Pantel, K.; Fleisher, M.; Scher, H. I.
The Cancer Journal (2011)

Fulltext@MSK | Save

Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel - Results from the COU-AA-301 phase 3 study

Meeting Abstract

Sternberg, C. N.; Scher, H. I.; Molina, A.; North, S.; Mainwaring, P.; Hao, Y.; Gagnon, D.; Kheoh, T.; Haqq, C. M.; de Bono, J.
European Journal of Cancer (2011)

Fulltext@MSK | Save

QT/QTc studies of abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) - Analysis of 3 phase 1/2 studies

Meeting Abstract

Ryan, C. J.; Danila, D. C.; Tolcher, A.; Chi, K. N.; Tran, N.; Knoblauch, R.; Kheoh, T.; Haqq, C. M.; Scher, H. I.; Molina, A.
European Journal of Cancer (2011)

Fulltext@MSK | Save

Abiraterone acetate improves functional status in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel - Results from the COU-AA-301 phase 3 study

Meeting Abstract

Harland, S.; de Bono, J. S.; Haqq, C. M.; Staffurth, J. N.; Hao, Y.; Gagnon, D.; Liu, C.; Sternberg, C. N.; Molina, A.; Scher, H. I.
European Journal of Cancer (2011)

Fulltext@MSK | Save